Oculis Holding AG (OCS) Research & Development (2022 - 2026)
Oculis Holding AG (OCS) posted quarterly Research & Development of -$17.9 million for Q1 2026, down 9.18% year-over-year from -$19.7 million in Q1 2025, and down 7.89% quarter-over-quarter from -$16.6 million in Q4 2025.
Oculis Holding AG (OCS) Research & Development (2022 - 2026) Analysis & Trends
Oculis Holding AG's Research & Development history runs 5 years deep, the most recent figure standing at -$17.9 million for Q1 2026.
- In Q1 2026, Research & Development fell 9.18% year-over-year to -$17.9 million; the TTM figure through Mar 2026 stood at -$17.7 billion (down 17.6% YoY), while the FY2025 annual figure was -$68.9 million, down 16.3% from the prior year.
- Research & Development for Q1 2026 stood at -$17.9 million, down from -$16.6 million in the prior quarter.
- The five-year high for Research & Development was -$4.8 million in Q3 2022, with the low at -$17.6 billion in Q3 2025.
- The 5-year median for Research & Development is -$12.9 million (2024), against an average of -$2.1 billion.
- The sharpest annual moves came in 2024 and 2025: Research & Development tumbled 149271.33% in 2024, then grew 1.09% in 2025.
- Oculis Holding AG's Research & Development stood at -$7.2 million in 2022, then retreated by 26.58% to -$9.1 million in 2023, then plunged by 48.35% to -$13.4 million in 2024, then declined by 23.82% to -$16.6 million in 2025, then slipped by 7.89% to -$17.9 million in 2026.
- Business Quant data shows OCS's Research & Development at -$17.9 million in Q1 2026, -$16.6 million in Q4 2025, and -$17.6 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Oculis Holding AG | 879.09 Mn | 590.21 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17.94 Mn |
| Dec 31, 2025 | -16.63 Mn |
| Sep 30, 2025 | -17.65 Bn |
| Jun 30, 2025 | -18.01 Mn |
| Mar 31, 2025 | -16.43 Mn |
| Dec 31, 2024 | -13.43 Mn |
| Sep 30, 2024 | -15.00 Bn |
| Jun 30, 2024 | -18.21 Mn |
| Mar 31, 2024 | -12.44 Mn |
| Dec 31, 2023 | -9.05 Mn |
| Sep 30, 2023 | -10.04 Mn |
| Jun 30, 2023 | -6.89 Mn |
| Mar 31, 2023 | -6.65 Mn |
| Dec 31, 2022 | -7.15 Mn |
| Sep 30, 2022 | -4.75 Mn |
| Jun 30, 2022 | -6.96 Mn |